1360 results about "Epidermal growth factor" patented technology

A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells.

The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

The invention provides human umbilical cord mesenchymal stem cell exosome type external cream and a preparation method thereof, and aims at the solving the problem in effectively inducing human umbilical cord mesenchymal stem cells to massively synthesize and secrete mesenchymal stem cell exosome capable of specifically promoting epidermis cell and hypodermal cell to proliferate, divide and differentiate, promoting the formation of collagenous fibers, reticular fibers and elastic fibers, and adjusting the secreting functions of collagen and mucopolysaccharide. The cream comprises human umbilical cord mesenchymal stem cell exosome extracting liquid and a base cream formula based on the mass ratio ranging from (1:20) to (3:10), wherein the human umbilical cord mesenchymal stem cell exosome extracting liquid is prepared by performing hungry culture on P2-P5 generations of human umbilical cord mesenchymal stem cells and stimulating through epidermal growth factors. The prepared cream has the effects of improving the skin quality, resisting the aging of skin cells, recovering the normal structure and physiological function of the skin, reducing the skin atrophy exsiccosis, and moisturizing the skin tissue.

The present invention relates to a cosmetic product with dispelling striae gravidarum effectiveness and a manufacturing method. Nutrient components synergy and can repair the elastic fiber effectively. Sweet almond oil and olive oil in the formula are rich in unsaturated fatty acid, which is totally identical with fats secretory of human; so essential fatty acid is added; the skin is repaired. Vitamin E has anti-aging and antioxidant effectiveness; small molecule faba bean peptide and nanometer parcel epidermal growth factor biomimetic peptide have strong physiological excitation signal which is easily absorbed by the skin; so the skin is stimulated to compose collagen which markedly amends the striae gravidarum. Centella asiatica extract can promote the composition of collagen I and III and can promote the composition of polysaccharide, which effective prevents and repairs the striae gravidarum.

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.